FIZE Medical Overview
FIZE Medical provides the first platform technology to remotely monitor and manage patients with an indwelling Foley catheter. The company developed and manufactures FIZE kUO device which enables digital real-time measurement of kidney urine output and key indicators of the health status of patients found in their urine with customizes alerts, allowing evidence based clinical decision-making . The Company’s device has been FDA registered and have been tested in clinical trials for efficacy and safety.
Cumulative Funding Raised Over Time ($)
$3.2MApr 2021
$7.2MDec 2021
$21.2MDec 2024
$23.2MMay 2020
Latest News
growth-positive
FIZE Medical Raises $30M in Series A
FIZE Medical, a fluid management optimization company based in Tel Aviv, has raised $30 million in Series A funding. The funding round was led by Rapha Capital Management and included participation from Valitas Venture Capital and eHealth Ventures. The company plans to use the funds to expand its market reach to the U.S., EU, and Asia, and to enhance its technological offerings. FIZE Medicals FIZE-kUO® device, which detects early signs of kidney deterioration, will benefit from AI-enabled algorithms for real-time treatment adjustments. The company is also preparing to launch AI-based predictive capabilities to improve patient outcomes.
InvestmentExpand
growth-positive
/PRNewswire/ -- FIZE Medical, a leader in fluid management optimization, is excited to announce the successful closure of its $30 million Series A funding...
FIZE Medical, a leader in fluid management optimization, has successfully closed a $30 million Series A funding round, including a $14 million Series A-4 round led by Rapha Capital Management. The company is expanding its geographical reach to the U.S., EU, and Asian markets and advancing its technological development with AI-based predictive capabilities. FIZE Medicals technology provides real-time monitoring of kidney output, helping medical teams adjust therapies promptly to improve patient outcomes. The funding will accelerate FIZE Medicals expansion into the U.S. and EU healthcare markets, with strategic partnerships with Cicor facilities in Vietnam and investors like Valitas Venture Capital and eHealth Ventures playing a critical role in this growth.
InvestmentExpandPartners
growth-positive
The company’s technology aims to improve hemodynamic status management, reducing mortality rates in intensive care units.
FIZE Medical, a company specializing in fluid management systems for critically ill patients, has raised $14 million in a funding round led by Rapha Capital. The company, which has raised a total of $29 million to date, aims to improve hemodynamic status management in intensive care units, potentially reducing mortality rates. The investment will support FIZE Medicals expansion into the U.S., Japan, and European markets, with plans to enhance production capabilities in Israel and Vietnam. The company is also collaborating with Cicor in Vietnam and expects to receive CE certification for European operations by 2025. New board observers from Valitas Ventures and eHealth Ventures will join as part of this expansion.
InvestmentExpandPartners
growth-positive
The company’s technology aims to improve hemodynamic status management, reducing mortality rates in intensive care units.
FIZE Medical, a company specializing in fluid management systems for critically ill patients, has raised $14 million in a funding round led by Rapha Capital. The company, founded in 2011, aims to improve hemodynamic status management in intensive care units, addressing high mortality rates. The investment will support FIZE Medicals expansion into the U.S., Japan, and European markets, with plans to enhance production capabilities in Israel and Vietnam. The company has already monitored over 4,000 patients in leading hospitals in the U.S. and Israel. Key partners include Valitas Ventures and eHealth Ventures, with representatives joining FIZE Medicals board as observers. The company is also collaborating with Cicor in Vietnam to expand production.
InvestmentExpandPartners
growth-positive
Israel's FIZE Medical donates advanced kidney devices to Soroka
In response to the October 7 massacre and the Israel-Hamas war, FIZE Medical donated several of its FIZE kUO kidney monitoring systems to Soroka Medical Center in Beersheba. The devices, which provide minute-by-minute digital UO monitoring with high resolution accuracy, were used to relieve the strain on the medical center, which treated some 680 patients in the first 16 hours following the massacre. The devices helped reduce mortality rates among patients suffering from acute kidney injury, and allowed for early detection of kidney function deterioration.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $24.2M |
| Last funding | $14M |
| Stage | A |
| Rounds | 5 |
| Investors | 4 |
Team Members
5
Employees: 11-50
Web & Social Links
| Website | fizemedical.com/ |
| Careers | Careers page |
Locations
HaShdera HaMerkazit 15, Modi'in Makabim-Re'ut, Israel
Photos & Videos
2 item(s)
FIZE Medical Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesMedical DevicesMedical MonitorsDigital HealthcarePatient Remote MonitoringTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareTags (14)
medical-devicesurologynephrologydigital-healthcaresoftware-applicationsdoctorsclinical-datadata-analyticsmonitoringautomationreal-timehospitalsremote-monitoringvital-signsGeographic Markets
IsraelNorth AmericaFIZE Medical Financials
$24.2M
Total funding
Undisclosed
Capital raised
$14M
Last funding
A
Funding stage
5
Total rounds
4
Investors
Cumulative Funding Raised Over Time ($)
$3.2MApr 2021
$7.2MDec 2021
$21.2MDec 2024
$23.2MMay 2020
Private Equity Funding
A Round
Dec 2024
$14M
Rapha Capital Management (Lead)
,
Valitas Ventures, eHealth Ventures
A Round
Dec 2021
$4M
Rapha Capital Management (Lead), Mendham Investment Group (Lead)
A Round
Apr 2021
$3.2M
Mendham Investment Group, Rapha Capital Management
A Round
May 2020
$2M
Rapha Capital Management (Lead)
Non-Equity Funding
GrantEvent
Feb 2024
$1M
Israel Innovation Authority
FIZE Medical Lifecycle
Cumulative Funding Raised Over Time
$3.2MApr 2021
$7.2MDec 2021
$21.2MDec 2024
$23.2MMay 2020
All Events
A Round
Dec 2024
$14M
Rapha Capital Management (Lead)
,
Valitas Ventures, eHealth Ventures
A Round
Dec 2021
$4M
Rapha Capital Management (Lead), Mendham Investment Group (Lead)
A Round
Apr 2021
$3.2M
Mendham Investment Group, Rapha Capital Management
A Round
May 2020
$2M
Rapha Capital Management (Lead)
GrantEvent
Feb 2024
$1M
Israel Innovation Authority
FIZE Medical News
6 articles
growth-positive
FIZE Medical Raises $30M in Series A
FIZE Medical, a fluid management optimization company based in Tel Aviv, has raised $30 million in Series A funding. The funding round was led by Rapha Capital Management and included participation from Valitas Venture Capital and eHealth Ventures. The company plans to use the funds to expand its market reach to the U.S., EU, and Asia, and to enhance its technological offerings. FIZE Medicals FIZE-kUO® device, which detects early signs of kidney deterioration, will benefit from AI-enabled algorithms for real-time treatment adjustments. The company is also preparing to launch AI-based predictive capabilities to improve patient outcomes.
InvestmentExpand
growth-positive
/PRNewswire/ -- FIZE Medical, a leader in fluid management optimization, is excited to announce the successful closure of its $30 million Series A funding...
FIZE Medical, a leader in fluid management optimization, has successfully closed a $30 million Series A funding round, including a $14 million Series A-4 round led by Rapha Capital Management. The company is expanding its geographical reach to the U.S., EU, and Asian markets and advancing its technological development with AI-based predictive capabilities. FIZE Medicals technology provides real-time monitoring of kidney output, helping medical teams adjust therapies promptly to improve patient outcomes. The funding will accelerate FIZE Medicals expansion into the U.S. and EU healthcare markets, with strategic partnerships with Cicor facilities in Vietnam and investors like Valitas Venture Capital and eHealth Ventures playing a critical role in this growth.
InvestmentExpandPartners
growth-positive
The company’s technology aims to improve hemodynamic status management, reducing mortality rates in intensive care units.
FIZE Medical, a company specializing in fluid management systems for critically ill patients, has raised $14 million in a funding round led by Rapha Capital. The company, which has raised a total of $29 million to date, aims to improve hemodynamic status management in intensive care units, potentially reducing mortality rates. The investment will support FIZE Medicals expansion into the U.S., Japan, and European markets, with plans to enhance production capabilities in Israel and Vietnam. The company is also collaborating with Cicor in Vietnam and expects to receive CE certification for European operations by 2025. New board observers from Valitas Ventures and eHealth Ventures will join as part of this expansion.
InvestmentExpandPartners
growth-positive
The company’s technology aims to improve hemodynamic status management, reducing mortality rates in intensive care units.
FIZE Medical, a company specializing in fluid management systems for critically ill patients, has raised $14 million in a funding round led by Rapha Capital. The company, founded in 2011, aims to improve hemodynamic status management in intensive care units, addressing high mortality rates. The investment will support FIZE Medicals expansion into the U.S., Japan, and European markets, with plans to enhance production capabilities in Israel and Vietnam. The company has already monitored over 4,000 patients in leading hospitals in the U.S. and Israel. Key partners include Valitas Ventures and eHealth Ventures, with representatives joining FIZE Medicals board as observers. The company is also collaborating with Cicor in Vietnam to expand production.
InvestmentExpandPartners
growth-positive
Israel's FIZE Medical donates advanced kidney devices to Soroka
In response to the October 7 massacre and the Israel-Hamas war, FIZE Medical donated several of its FIZE kUO kidney monitoring systems to Soroka Medical Center in Beersheba. The devices, which provide minute-by-minute digital UO monitoring with high resolution accuracy, were used to relieve the strain on the medical center, which treated some 680 patients in the first 16 hours following the massacre. The devices helped reduce mortality rates among patients suffering from acute kidney injury, and allowed for early detection of kidney function deterioration.
CustomersPartners
growth-positive
Rapha Capital Management Leads Series A Financing for FIZE Medical Inc.
Rapha Capital Management led FIZE Medical Inc.s Series A financing with a $2 million investment. The funding will be used to develop and launch FIZEs novel device for measuring urine output in real time. The device aims to improve healthcare worker safety, patient care, and overall efficiency in hospitals. Kevin Slawin, founder of Rapha Capital Management, joined FIZEs board as a result of the financing. The COVID-19 pandemic has increased the demand for technologies that protect healthcare workers and enhance patient care. Rapha Capital Management is an investment management firm focused on early-stage biotechnology companies. FIZE Medical is developing a platform of assays to measure health indicators in urine.
Investment
FIZE Medical Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 48 |
| Team members | 5 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 10 classification IDs that could be used for matching.
FIZE Medical Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yotam Maman |
| Registrar ID | 514606342 |
| Crunchbase | fize-medical |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-12-18T00:00:00.000Z |
| Created | 2021-01-25T00:00:00.000Z |
| Claimed | Yes |